Economic evaluation of plerixafor for stem cell mobilization

American Journal of Managed Care

Volumn 18, Issue 1, 2012, Pages 33-41

  Kymes, Steven M ^a,b   Pusic, Iskra ^c   Lambert, Dennis L ^a   Gregory, Martin ^a   Carson, Kenneth R ^c   DiPersio, John F ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR; VALACICLOVIR;

APHERESIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION;

COSTS AND COST ANALYSIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MARKOV CHAINS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84856770362     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Child JA, Morgan GJ, Davies FE, et al Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-1883. (Pubitemid 36532313)
2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
3. Villanueva ML, Vose JM. The role of hematopoietic stem cell transplantation in non-Hodkgin lymphoma. Clin Adv Hematol Oncol. 2006;4(7):521-530. (Pubitemid 44251581)
4. Jansen J, Thompson JM, Dugan MJ, et al. Peripheral blood progenitor cell transplantation. Ther Apher. 2002;6(1):5-14. (Pubitemid 34218722)
5. Dreger P, Viehmann K, Steinmann J, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol. 1995;23(2):147-154.
6. Tarella C, Di Nicola M, Caracciolo D, et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant. 2002;30(11):725-732. (Pubitemid 36007752)
7. Meehan KR, Hill JM, Patchett L, et al. Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. Transfusion (Paris). 2006;46(4):523-529.
8. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990-998.
9. Flomenberg N, DiPersio J, Calandra G, Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol. 2005;114(4):198-205. (Pubitemid 41567002)
10. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9): 1045-1056.
11. DiPersio JF, Micallef IN, Stiff PJ, et al; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
12. Weinstein MC. Recent developments in decision-analytic modeling for economic evaluation. Pharmacoeconomics. 2006;24(11):1043-1053. (Pubitemid 44683362)
13. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 5-working with Markov processes. Med Decis Making. 1997;17(2):152-159. (Pubitemid 27157030)
14. Fenske TS, Hari PN, Carreras J, et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009;15(11):1455-1464.
15. Stiggelbout AM, de Haes JC, Kiebert GM, Kievit J, Leer JW. Tradeoffs between quality and quantity of life: development of the QQ questionnaire for cancer patient attitudes. Med Decis Making. 1996;16(2): 184-192. (Pubitemid 26108911)
16. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5(1):1-30. (Pubitemid 16098443)
17. van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial. Eur J Cancer. 2001;37(14):1781-1789. (Pubitemid 32817053)
18. Doorduijn J, Buijt I, Holt B, Steijaert M, Groot CU-d, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non- Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol. 2005;75(2):116-123. (Pubitemid 41008281)
19. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Löwenberg B, Rutten F. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant. 1995;16(3):463-470.
20. Lee BS, Kymes SM, Nease RF Jr, Sumner W, Siegfried CJ, Gordon MO. The impact of anchor point on utilities for 5 common ophthalmic diseases. Ophthalmology. 2008;115(5):898-903.e4.
21. Lindgren P, Kahan T, Poulter N, et al. Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. Eur J Health Econ. 2007;8(1):25-30. (Pubitemid 46295335)
22. Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 4-analyzing the model and interpreting the results. Med Decis Making. 1997;17(2):142-151. (Pubitemid 27157029)
23. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8): 779-787. (Pubitemid 34041389)
24. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. BMJ. 2007;335(7616):358-359. (Pubitemid 47359304)
25. Glennie JL, Torrance GW, Baladi JF, et al. The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics. 1999;15(5):459-468. (Pubitemid 29210949)
26. Gillick MR. Medicare coverage for technological innovations-time for new criteria? N Engl J Med. 2004;350(21):2199-2203. (Pubitemid 38659502)
27. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase with the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641. (Pubitemid 36898950)
28. Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess. 2004;8(37):iii, ix-xi, 1-82.
29. Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Health Technol Assess. 2009;13(suppl 2):41-48.
30. Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol. 2008;47(6):1029- 1036.
31. Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Investig. 2008;28(1):55-65. (Pubitemid 350274401)
32. Best JH, Hornberger J, Proctor SJ, Omnes LF, Jost F. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health. 2005;8(4):462-470. (Pubitemid 41726099)
33. Deconinck E, Miadi-Fargier H, Pen CL, Brice P. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics. 2010;28(1):35-46.
34. Lee RC, Zou D, Demetrick DJ, Difrancesco LM, Fassbender K, Stewart D. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center. Value Health. 2008;11(2):221-230. (Pubitemid 351473604)
35. Fagnoni P, Milpied N, Limat S, et al Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang. Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma. Pharmacoeconomics. 2009; 27(1):55-68.